

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ljunggren and Svensson

Title: Use Of ATII Antagonist For The Treatment Or Prevention Of Metabolic Syndrome

Serial No.: 10/550,760

Group Art Unit: 1628

Filed: September 27, 2005

Examiner: Timothy P. Thomas

Confirmation No.: 3784

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

DECLARATION OF ANDERS LJUNGGREN

I, Anders Ljunggren, do hereby declare as follows:

1. I am a research scientist at AstraZeneca AB and am an inventor of the above-identified patent application; I have worked in the cardiovascular field since 1973.
2. I have examined and am familiar with the Office Action dated December 14, 2009.
3. I have examined and am familiar with U.S. Patent Application Publication US 2003-0187038 published on October 2, 2003 (hereinafter referred to as the "Imura reference"), which is cited and referred to in the Office Action dated December 14, 2009.
4. Paragraph [0156] of the Imura reference recites a list of purported "fibrinogen-related diseases" which includes well more than one hundred diseases or conditions.
5. Paragraph [0156] of the Imura reference recites "syndrome X" as an example of a "metabolic disorder" within the list of purported "fibrinogen-related diseases."

6. The Imura reference provides no data to support the position that "syndrome X" is a fibrinogen-related disease.
7. The Imura reference provides no citation to support the position that "syndrome X" is a fibrinogen-related disease.
8. I am not aware of any causative link between fibrinogen levels in a human and syndrome X or metabolic syndrome in a human.
9. I declare that all statements made herein are of our own knowledge true and statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Anders Ljunggren

2010-04-27
Date